ABOUT US
TECHNOLOGY
PIPELINE
PARTNERSHIP
MEDIA
RECRUITMENT
CONTACT
EN
EN

ABOUT US

Home

ABOUT US

COMPANY INTRODUCTION
GENEQUANTUM HEALTHCARE
(SUZHOU) CO., LTD.
GeneQuantum, headquartered in China, is a global leader in the ADC field, distinguished for its advancement of enzymatic site-specific conjugation technologies. Our pioneering technologies, iLDC and iGDC, serve as the foundation of our comprehensive ADC drug development platform, spanning from the initial design to seamless commercial production.

The technology offered by GQ provides numerous advantages, such as exceptional product homogeneity, elevated process quality, and enhanced metabolic stability. Our continuous conjugation process seamlessly integrates with standard antibody production, ensuring the efficient creation of high-quality ADC drugs that rival the efficiency of antibody drugs.
GQ's integrated approach leads to a substantial reduction in commercial production costs for ADCs. GQ remains steadfast in its commitment to delivering vital technical support, expediting global ADC drug development. Our dedication to collaborative synergy underpins mutual growth and success across diverse domains of ADC development.
Our vision
Our vision is to enhance global affordability and expand worldwide access to innovative ADC therapies, fulfilling truly unmet medical needs
HISTORY
Aug 2013
Company incorporated in bioBay, Suzhou Industrial Park, China
Jul 2015
Selected as a leading talent for innovation and entrepreneurship in Suzhou
Mar 2017
GeneQuantum completed RMB 40 million Yuan Series A financing
Aug 2013
Company incorporated in bioBay, Suzhou Industrial Park, China
Jul 2015
Selected as a leading talent for innovation and entrepreneurship in Suzhou
Mar 2017
GeneQuantum completed RMB 40 million Yuan Series A financing

2013-2017

Aug 2013
Company incorporated in bioBay, Suzhou Industrial Park, China
Jul 2015
Selected as a leading talent for innovation and entrepreneurship in Suzhou
Mar 2017
GeneQuantum completed RMB 40 million Yuan Series A financing
Aug 2013
Company incorporated in bioBay, Suzhou Industrial Park, China
Jul 2015
Selected as a leading talent for innovation and entrepreneurship in Suzhou
Mar 2017
GeneQuantum completed RMB 40 million Yuan Series A financing

2018-2020

Sept 2019
GeneQuantum completed Pre-B round of financing
Dec 2019
GQ1001 Australian clinical trial approved
May 2020
GQ1001 US clinical trial approved
Jul 2020
GQ1001 completed dosing of first subject in Australia
Oct 2020
Completed Series B financing
Sept 2019
GeneQuantum completed Pre-B round of financing
Dec 2019
GQ1001 Australian clinical trial approved
May 2020
GQ1001 US clinical trial approved
Jul 2020
GQ1001 completed dosing of first subject in Australia
Oct 2020
Completed Series B financing

2021-2023

May 2021
GeneQuantum completed hundreds of millions of RMB Series C financing
Nov 2021
Awarded as the ‘Potential Unicorn’ in Jiangsu Province
Jan 2022
GeneQuantum Global R&D Headquarter opening
Apr 2022
GeneQuantum and Aimed sign Global Collaboration Agreement on First-in-class ADC Drugs
Apr 2022
GeneQuantum's Next Generation GQ1005 and First AIAC DrugGQ1007 are approved for Clinical Use in Australia
Sept 2022
U.S. Patent Approved for LDC Technology
Dec 2022
GQ1005 completed dosing of first subject
Dec 2022
GeneQuantum enters a Strategic collaboration with WuXi XDC
Apr 2023
GeneQuantum enters License Agreement with Pyramid
Apr 2023
GeneQuantum enters a strategic collaboration with Asymchem
May 2023
GeneQuantum enters a strategic collaboration with Thousand Oaks Biologics
May 2023
GeneQuantum enters a strategic collaboration with Intellective Biologics
Jun 2023
Awarded the ‘China Potential Unicorn’
Jul 2023
GeneQuantum enters a strategic collaboration with InxMed
Nov 2023
GeneQuantum enters a strategic collaboration with Nona Biosciences
May 2021
GeneQuantum completed hundreds of millions of RMB Series C financing
Nov 2021
Awarded as the ‘Potential Unicorn’ in Jiangsu Province
Jan 2022
GeneQuantum Global R&D Headquarter opening
Apr 2022
GeneQuantum and Aimed sign Global Collaboration Agreement on First-in-class ADC Drugs
Apr 2022
GeneQuantum's Next Generation GQ1005 and First AIAC DrugGQ1007 are approved for Clinical Use in Australia
Sept 2022
U.S. Patent Approved for LDC Technology
Dec 2022
GQ1005 completed dosing of first subject
Dec 2022
GeneQuantum enters a Strategic collaboration with WuXi XDC
Apr 2023
GeneQuantum enters License Agreement with Pyramid
Apr 2023
GeneQuantum enters a strategic collaboration with Asymchem
May 2023
GeneQuantum enters a strategic collaboration with Thousand Oaks Biologics
May 2023
GeneQuantum enters a strategic collaboration with Intellective Biologics
Jun 2023
Awarded the ‘China Potential Unicorn’
Jul 2023
GeneQuantum enters a strategic collaboration with InxMed
Nov 2023
GeneQuantum enters a strategic collaboration with Nona Biosciences

2024-2026

Apr 2024
GQ1010 is approved for Clinical Use in China and Australia
May 2024
GeneQuantum and Tsinghua University signed Collaboration Agreement
May 2024
GQ1010 completed dosing of first subject in phase I/II
Aug 2024
GeneQuantum joined Johnson & Johnson Innovation _JLABS @ Shanghai
Sep 2024
GQ1005 is approved for Phase III clinical trial
Sep 2024
GeneQuantum released the latest data of GQ1005 in the form of an oral report at WCLC 2024
Jan 2025
The intelligent automated discovery system for bioconjugate drugs（iDiscovery）has been launched
Jan 2025
Signed a Major Business Cooperation with a Total Amount Exceeding 1.3 Billion US Dollars
Aug 2025
GeneQuantum and Henlius Entered into Strategic Cooperation to Jointly Advance the Commercialization of Innovative ADC Drug GQ1005
Apr 2024
GQ1010 is approved for Clinical Use in China and Australia
May 2024
GeneQuantum and Tsinghua University signed Collaboration Agreement
May 2024
GQ1010 completed dosing of first subject in phase I/II
Aug 2024
GeneQuantum joined Johnson & Johnson Innovation _JLABS @ Shanghai
Sep 2024
GQ1005 is approved for Phase III clinical trial
Sep 2024
GeneQuantum released the latest data of GQ1005 in the form of an oral report at WCLC 2024
Jan 2025
The intelligent automated discovery system for bioconjugate drugs（iDiscovery）has been launched
Jan 2025
Signed a Major Business Cooperation with a Total Amount Exceeding 1.3 Billion US Dollars
Aug 2025
GeneQuantum and Henlius Entered into Strategic Cooperation to Jointly Advance the Commercialization of Innovative ADC Drug GQ1005
MANAGEMENT TEAM
Gang Qin, Ph.D., CEO
Gang Qin, Ph.D., CEO
Founder/Chairman
More
Paul H.Song, Ph.D., CSO
Paul H.Song, Ph.D., CSO
Innovation Drug R&D and Pipeline building
More
Amy Hong Que, Ph.D., CTO
Amy Hong Que, Ph.D., CTO
Responsible for CMC and Quality
More
Gang Qin, Ph.D., CEO
Founder/Chairman
return

Experience:

Post-Doc, Max-Planck Institute of Biochemistry

Project Leader of DFG, Max-Planck Institute of Biochemistry

Principal lnvestigator, Tianjin lnstitute of lndustrial Biotechnology, Chinese Academy of Sciences

Leading Science & Technology Entrepreneur Talents Nanjing 321

Leading Entrepreneur Talents Suzhou Industrial Park



Education:

Nankai University, BS Biochemistry/MS Molecular biology

Georg-August-Universität/Max-Planck lnstitute of Biophysical Chemistry, Goettingen, Germany, Ph.D Neurobiology


Paul H.Song, Ph.D., CSO
Innovation Drug R&D and Pipeline building
return

Responsibilities:

Establishing a world-class R&D structure specializing in bioconjugates, integrating innovative science and cutting-edge technologies.

Leading the development of next generation first/best-in-class bioconjugate drug pipelines that significantly advance the current treatment landscape.

Leading technology innovation at GQ, focusing on unique iLDC/iGDC conjugation technologies, stable linker technologies, and novel payload development.


Experience:

Chief Scientific Officer (CSO) at Curon Biopharmaceutical, China

Vice President (VP) at Samsung Bioepis, Korea

Principal Research Scientist at Eli Lilly Research Laboratories, USA

Post-Doctoral Researcher at Tularik Inc. (Amgen SF), USA


Education:

Ph.D. in Biology from Purdue University, USA


Amy Hong Que, Ph.D., CTO
Responsible for CMC and Quality
return

Responsibilities:

Establish and optimize GMP quality system

Responsible for CMC development and manufacturing to ensure the smooth progress of the projects



Experience:

Chief Technology Officer, Harbour BioMed, Suzhou/Shanghai, PR China

Senior Vice President, Innovent Biologics, Suzhou, PR China

Vice President, WuXi Biologics, Shanghai , PR China

Vice President, Sinocell Tech, Beijing, PR China



Education:

Ph.D., Bioanalytical Chemistry, Indiana University, Bloomington